Now Offering Brainsway dTMS: a safe and non-invasive treatment that uses Deep Transcranial Magnetic Stimulation (TMS) to Treat Depressive Disorder.
Standard Transcranial Magnetic Stimulation (TMS)
Standard TMS involve repetitive interference with the brain electrical activity, which induces high levels of neural activity while it is being delivered, and long-lasting effects thereafter. Brief repetitive stimulation triggers a process of learning and a state of plasticity in the brain, which allow long-lasting effects to be exerted on neural activity in target brain areas.
BrainsWay D for Depression
BrainsWay D* for depression offers an effective*, safe and non-invasive treatment that uses Deep Transcranial Magnetic Stimulation (TMS) to treat major depressive disorder. The treatment performs magnetic stimulation of the brain region responsible for depression and brings significant improvement to patients. It is an outpatient procedure and does not require hospitalization or anesthesia, is generally well tolerated and entails minimal systemic side effects*.
Clinical Trials
BrainsWay has conducted a clinical trial* using Deep TMS (deep transcranial magnetic stimulation) for depression treatment*: Major Depression – Multicenter Double Blind Randomized Controlled Trial for Tolerability, Safety and Efficacy of the H-Coil Deep TMS. Click here for more information about this clinical trial.
Following this trial, the FDA granted wide indication for BrainsWay D for depression to be used in cases of treatment-resistant depression in patients who did not benefit from any number of previous medication treatments. BrainsWay D for depression is approved by the FDA and by ANVISA for treating major depressive disorder*.
Real Life Clinical Practice using BrainsWay D for Depression
In real-life clinical practice settings, 20 sessions of BrainsWay D resulted in remission rates that were even higher than those observed in randomized controlled clinical trials1. Among patients who went on to complete a treatment course of 30 sessions, 1 in 2 achieved full remission, suggesting a definite benefit for patients completing the full 30-session treatment regimen.